drugset / Trial / NCT04052334
Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma
Phase 1
Completed
9 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Iovance Biotherapeutics, Inc. · collabNational Cancer Institute (NCI) · collabThe V Foundation for Cancer Research · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm trial that will evaluate the safety and feasibility of the Tumor-infiltrating lymphocyte (TIL) treatment and the persistence of TIL survival in vivo following treatment
Timeline
- Start
- 2019-09-27
- Primary completion
- 2023-05-26
- Completion
- 2023-06-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TIL | Unknown | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 60 mg/kg | Intravenous |
| Background | Fludarabine | Small molecule | 25 mg/m2 | Intravenous |
| Background | aldesleukin | Protein / enzyme biologic | 600000 iu/kg | Intravenous |